[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 35 of about 35
1. Meany HJ, Seibel NL, Sun J, Finklestein JZ, Sato J, Kelleher J, Sondel P, Reaman G: Phase 2 trial of recombinant tumor necrosis factor-alpha in combination with dactinomycin in children with recurrent Wilms tumor. J Immunother; 2008 Sep;31(7):679-83
Hazardous Substances Data Bank. DACTINOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 trial of recombinant tumor necrosis factor-alpha in combination with dactinomycin in children with recurrent Wilms tumor.
  • Tumor necrosis factor (TNF), a peptide produced by macrophages with cytostatic and cytolytic effects, demonstrated single agent antitumor activity and synergistic effect when administered with dactinomycin in in vitro tumor cell lines, in vivo xenograft models, and adult and pediatric phase 1 clinical trials.
  • This phase 2 pediatric trial evaluated the efficacy and further defined the toxicity profile of recombinant TNF (rTNF) and dactinomycin in patients with recurrent or refractory Wilms tumor.
  • On this 2 stage Children's Cancer Group trial, dactinomycin (15 microg/kg/d, IV) immediately followed by rTNF (200 microg/m/d, IV), once daily for 5 consecutive days, was administered to patients with recurrent or refractory Wilms tumor.
  • Nineteen of 21 consecutive patients, ranging 0.9 to 16.5 years of age at the time of initial diagnosis, were evaluable for response and toxicity.
  • Following 59 patient treatment cycles, the most commonly observed grade 3/4 toxicities were thrombocytopenia (40.7%), elevated liver transaminases (23.7%), neutropenia (20.3%), leucopenia (13.6%), anemia (11.9%), and myalgias (10.2%).
  • The documented complete responses and disease stabilization suggest antitumor activity of rTNF with dactinomycin in patients with recurrent Wilms tumor.

  • Genetic Alliance. consumer health - Familial Wilms Tumor 2.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Pediatr Oncol. 2003 Nov;41(5):483-5 [14515398.001]
  • [Cites] Pediatr Blood Cancer. 2007 May;48(5):493-9 [16547940.001]
  • [Cites] Cancer Res. 1984 Jan;44(1):83-90 [6690064.001]
  • [Cites] Jpn J Cancer Res. 1985 Jul;76(7):631-6 [3928560.001]
  • [Cites] Int J Immunopharmacol. 1986;8(3):347-55 [3525433.001]
  • [Cites] J Cell Physiol. 1987 Mar;130(3):328-35 [3470296.001]
  • [Cites] Cancer Res. 1987 Jun 1;47(11):2986-9 [3567916.001]
  • [Cites] Cancer Res. 1987 May 1;47(9):2403-6 [2436763.001]
  • [Cites] J Clin Oncol. 1987 Dec;5(12):1942-51 [3681377.001]
  • [Cites] Immunopharmacol Immunotoxicol. 1988;10(1):117-27 [2452179.001]
  • [Cites] J Clin Oncol. 1988 Aug;6(8):1328-34 [3411344.001]
  • [Cites] Prog Growth Factor Res. 1989;1(2):107-22 [2491255.001]
  • [Cites] J Clin Oncol. 1993 Nov;11(11):2205-10 [8229135.001]
  • [Cites] J Immunother Emphasis Tumor Immunol. 1994 Aug;16(2):125-31 [7804527.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):237-45 [9440748.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5893-9 [16115931.001]
  • [Cites] Oncologist. 2005 Nov-Dec;10(10):815-26 [16314292.001]
  • [Cites] Cancer Immun. 2006;6:6 [16551058.001]
  • [Cites] JAMA. 1966 Nov 21;198(8):826-36 [4288581.001]
  • (PMID = 18600176.001).
  • [ISSN] 1537-4513
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA013539; United States / NCI NIH HHS / CA / CA013539-29; United States / NCI NIH HHS / CA / U10 CA013539-29; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA098543-01
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / Tumor Necrosis Factor-alpha; 1CC1JFE158 / Dactinomycin
  • [Other-IDs] NLM/ NIHMS107700; NLM/ PMC2677078
  •  go-up   go-down


2. Park ES, Kang HJ, Shin HY, Ahn HS: Improved survival in patients with recurrent Wilms tumor: the experience of the Seoul National University Children's Hospital. J Korean Med Sci; 2006 Jun;21(3):436-40
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival in patients with recurrent Wilms tumor: the experience of the Seoul National University Children's Hospital.
  • The survival in cases with relapsed Wilms tumor is dismal.
  • Recently, however the introduction of new therapeutic agents and experimental strategies has improved the survival.
  • We analysed the survival of patients with relapsed Wilms tumor according to the treatment period.
  • During the early period 1983-1993, patients who had received two drugs were treated with doxorubicin and the others were treated with cisplatin and etoposide, whereas during the late period 1994-2004, patients were treated with combinations of cyclophosphamide/etoposide and carboplatin/etoposide.
  • During the early period, 8 of 57 experienced relapse, and 8 of 41 relapsed during the late period.
  • Only 2 patients treated during the early period survived in complete response (CR), whereas during the late period, 5 patients remained alive in CR, and 3 of those received high-dose chemotherapy (HDC) with autologous peripheral stem cell rescue (SCR).
  • The survival in patients with relapsed Wilms tumor dramatically improved during the late period and HDC with SCR was one of the effective salvage strategies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Peripheral Blood Stem Cell Transplantation. Recurrence. Wilms Tumor / mortality. Wilms Tumor / pathology
  • [MeSH-minor] Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Korea. Male. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2002 Mar;13(3):460-9 [11996479.001]
  • [Cites] Bone Marrow Transplant. 2002 Dec;30(12):893-8 [12476282.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2885-90 [15254057.001]
  • [Cites] Cancer. 1976 Aug;38(2):633-46 [184912.001]
  • [Cites] J Clin Oncol. 1988 May;6(5):793-6 [2835442.001]
  • [Cites] J Clin Oncol. 1989 May;7(5):638-47 [2540289.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3295-301 [9779704.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1898-903 [8448755.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1478-81 [8393095.001]
  • [Cites] Med Pediatr Oncol. 1994;22(1):11-4 [8232074.001]
  • [Cites] Cancer. 1994 Feb 15;73(4):1297-301 [8313334.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):931-6 [8164044.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Aug;17(3):265-9 [7620926.001]
  • [Cites] Cancer. 1991 Feb 1;67(3):567-71 [1845951.001]
  • (PMID = 16778385.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2729947
  •  go-up   go-down


3. Tucci S Jr, Cologna AJ, Suaid HJ, Valera ET, Tirapelli LF, Paschoalin EL, Martins AC: Results of novel strategies for treatment of Wilms' tumor. Int Braz J Urol; 2007 Mar-Apr;33(2):195-201; discussion 201-3
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of novel strategies for treatment of Wilms' tumor.
  • OBJECTIVE: To evaluate treatment outcomes in Wilms' tumor (WT).
  • Treatment consisted of surgical excision plus adjuvant (40 children) or neoadjuvant and adjuvant chemotherapy (unresectable tumor, n=8, or caval tumor extension, n=5).
  • Chemotherapy and radiotherapy followed protocols of Brazilian Wilms' Tumor Study Group excepting 16 cases with stage I disease that received a short duration postoperative treatment with vincristine (VCR - 11 doses) and dactinomycin (AMD - 4 doses).
  • Relapsed WT was treated with multiagent regimens including cisplatin/carboplatin, cyclophosphamide, ifosfamide and etoposide.
  • One patient with resistant relapsed WT was treated by high-dose conditioning chemotherapy with stem cell rescue.
  • Short duration therapy for stage I tumor showed a disease-free survival rate of 100% in a median time of 101 months (range 14 to 248 months).
  • Overall and disease-free survival of 10 patients with recurrent WT at 5 years was 42.8%.
  • The child treated with high-dose chemotherapy plus stem cell transplant is alive without evidence of disease 84 months from relapse.
  • CONCLUSION: The postoperative chemotherapy in stage I disease can be reduced without compromising the cure rate.
  • The treatment of unfavorable stage III and IV disease or relapsed tumor remains a challenge.
  • [MeSH-major] Kidney Neoplasms / surgery. Wilms Tumor / surgery
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy / methods. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infant. Male. Neoplasm Staging. Nephrectomy. Recurrence

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int Braz J Urol. 2007 May-Jun;33(3):424-5 [17626664.001]
  • (PMID = 17488540.001).
  • [ISSN] 1677-5538
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


Advertisement
4. Metzger ML, Dome JS: Current therapy for Wilms' tumor. Oncologist; 2005 Nov-Dec;10(10):815-26
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current therapy for Wilms' tumor.
  • Wilms' tumor was the first solid malignancy in which the value of adjuvant chemotherapy was established.
  • Multimodality treatment has resulted in a significant improvement in outcome from approximately 30% in the 1930s to more than 85% in the modern era.
  • Although the National Wilms' Tumor Study Group and the International Society of Pediatric Oncology differ philosophically regarding the merits of preoperative chemotherapy, outcomes of patients treated with either up-front nephrectomy or preoperative chemotherapy have been excellent.
  • The goal of current clinical trials is to reduce therapy for children with low-risk tumors, thereby avoiding acute and long-term toxicities.
  • At the same time, current clinical trials seek to augment therapy for patients with high-risk Wilms' tumor, including those with bilateral, anaplastic, and recurrent favorable histology tumors.
  • [MeSH-major] Kidney Neoplasms / therapy. Wilms Tumor / therapy

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314292.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / CA87903
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 109
  •  go-up   go-down


5. Huang J, Soffer SZ, Kim ES, McCrudden KW, Huang J, New T, Manley CA, Middlesworth W, O'Toole K, Yamashiro DJ, Kandel JJ: Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res; 2004 Jan;2(1):36-42
Hazardous Substances Data Bank. Topotecan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis.
  • The potential for avoiding acquired resistance to therapy has been proposed as one compelling theoretical advantage of antiangiogenic therapy based on the normal genetic status of the target vasculature.
  • However, previous work has demonstrated that tumors may resume growth after initial inhibition if antiangiogenic blockade is continued for an extended period.
  • The mechanisms of this recurrent growth are unclear.
  • In these studies, we characterized molecular changes in vasculature during apparent resumption of xenograft growth after initial inhibition by vascular endothelial growth factor blockade, "metronome" topotecan chemotherapy, and combined agents in a xenograft murine model of human Wilms' tumor.
  • Tumors that grew during antiangiogenic blockade developed as viable clusters surrounding strikingly remodeled vessels.
  • Thus, enhanced vascular stability appears to characterize tumor vessel response to chronic antiangiogenesis, features that potentially support increased perfusion and recurrent tumor growth.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasm Recurrence, Local. Neovascularization, Pathologic / drug therapy. Topotecan / therapeutic use. Wilms Tumor / blood supply
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Biomarkers, Tumor / metabolism. Ephrin-B2 / metabolism. Female. Fluorescein Angiography. Fluorescent Antibody Technique, Indirect. Humans. In Situ Hybridization. Mice. Mice, Nude. Microscopy, Fluorescence. Neoplasm Proteins / metabolism. Proto-Oncogene Proteins c-sis / metabolism. Receptor, Platelet-Derived Growth Factor beta / metabolism. Transplantation, Heterologous. Vascular Endothelial Growth Factor A / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14757844.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R01 CA 088951-01A1; United States / NCI NIH HHS / CA / U10 CA 13539-27
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Ephrin-B2; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-sis; 0 / Vascular Endothelial Growth Factor A; 7M7YKX2N15 / Topotecan; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  •  go-up   go-down


6. Dome JS, Liu T, Krasin M, Lott L, Shearer P, Daw NC, Billups CA, Wilimas JA: Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude Children's Research Hospital. J Pediatr Hematol Oncol; 2002 Mar-Apr;24(3):192-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude Children's Research Hospital.
  • BACKGROUND: Reported estimates of survival for patients with recurrent Wilms tumor are 24% to 43%.
  • Because published survival data are more than a decade old and do not reflect advances in therapy, the authors reviewed their experience in treating recurrent Wilms tumor to determine whether the probability of survival has increased.
  • PATIENTS AND METHODS: The authors reviewed the cases of 54 patients with recurrent Wilms tumor who were treated on one of six consecutive clinical trials at St. Jude Children's Research Hospital between 1969 and 2000.
  • Only three patients received high-dose chemotherapy with autologous stem cell rescue; one survived.
  • No patients with recurrent anaplastic histology disease survived.
  • CONCLUSIONS: Significant progress has been achieved in the treatment of recurrent favorable-histology Wilms tumor using multimodality salvage regimens with conventional doses of chemotherapy.
  • Novel therapeutic strategies will be necessary to cure patients with recurrent anaplastic Wilms tumor.
  • [MeSH-major] Kidney Neoplasms / mortality. Neoplasm Recurrence, Local / mortality. Wilms Tumor / mortality
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Hospitals, Pediatric. Humans. Infant. Male. Neoplasm Staging. Nephrectomy. Prognosis. Radiotherapy. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Curr Urol Rep. 2003 Apr;4(2):141 [12648431.001]
  • (PMID = 11990305.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Brown E, Hebra A, Jenrette J, Hudspeth M: Successful treatment of late, recurrent wilms tumor with high-dose chemotherapy and autologous stem cell rescue in third complete response. J Pediatr Hematol Oncol; 2010 Aug;32(6):e241-3
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of late, recurrent wilms tumor with high-dose chemotherapy and autologous stem cell rescue in third complete response.
  • SUMMARY: Wilms tumor relapses are infrequent, occurring in approximately 15% of favorable histology patients.
  • Very few cases of late recurrent relapse exist in the literature.
  • We report a late recurrent relapse of Wilms tumor successfully treated with high-dose chemotherapy and autologous stem cell rescue in his third complete response who remains disease free 15 months posttransplant.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Kidney Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Wilms Tumor / therapy
  • [MeSH-minor] Adolescent. Carboplatin / administration & dosage. Child, Preschool. Combined Modality Therapy. Etoposide / administration & dosage. Humans. Male. Melphalan / administration & dosage. Salvage Therapy / methods

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20628317.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; Q41OR9510P / Melphalan
  •  go-up   go-down


8. Presson A, Moore TB, Kempert P: Efficacy of high-dose chemotherapy and autologous stem cell transplant for recurrent Wilms' tumor: a meta-analysis. J Pediatr Hematol Oncol; 2010 Aug;32(6):454-61
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of high-dose chemotherapy and autologous stem cell transplant for recurrent Wilms' tumor: a meta-analysis.
  • SUMMARY: Long-term survival of relapsed Wilms' tumor patients is about 40% to 70%.
  • Modern second-line treatment consists of either (a) salvage chemotherapy+/-radiation therapy (CT) or (b) chemotherapy followed by high-dose chemotherapy and autologous hematopoietic stem cell rescue (ASCR).
  • Here, we conduct an individual patient data meta-analysis on 100 patients collected from 6 studies to determine characteristics that predict survival in relapsed patients who received ASCR therapy.
  • The ASCR patients who only relapsed in the lungs had higher 4-years survival rates 77.7% (58.6% to 88.8%) than those who relapsed in other locations and/or suffered multiple relapses 41.6% (24.8% to 57.6%).
  • Although lung-only relapse is considered a favorable prognostic factor, there was no clear advantage for the patients treated with salvage chemotherapy.
  • These findings suggest salvage chemotherapy is typically the better choice for relapsed Wilms' tumor patients, ASCR could be considered for stage III-IV patients with a lung-only relapse.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Kidney Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Salvage Therapy / methods. Wilms Tumor / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Kaplan-Meier Estimate. Male. Neoplasm Staging. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20505538.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Spreafico F, Pritchard Jones K, Malogolowkin MH, Bergeron C, Hale J, de Kraker J, Dallorso S, Acha T, de Camargo B, Dome JS, Graf N: Treatment of relapsed Wilms tumors: lessons learned. Expert Rev Anticancer Ther; 2009 Dec;9(12):1807-15
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of relapsed Wilms tumors: lessons learned.
  • Treatment regimens for recurrent Wilms tumor (WT) are currently designed to include drugs that are not used during primary chemotherapy, using a risk-stratified approach.
  • Therapy of recurrent disease depends on the nature of initial treatment, and of recognized prognostic indicators inherent in the primary tumor.
  • Several highly effective chemotherapy regimens, including ifosfamide-carboplatin-etoposide, cyclophosphamide-etoposide and carboplatin-etoposide, are considered first treatment choice for recurrent disease.
  • While intense-dose chemotherapy is uniformly accepted to treat high-risk recurrent WTs, the optimal therapy for standard-risk children has yet to be defined, owing to the small number of such patients and their relatively better prognosis compared with high-risk recurrences.
  • Recurrent tumors among those defined as very-high risk are likely to develop chemoresistant disease, and novel therapeutic strategies will be necessary to cure these patients.
  • The authors have reviewed the available experiences concerning the treatment of recurrent WT, and have attempted to provide the most up-to-date recommendations regarding the optimal risk-based treatment for these patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / therapy. Wilms Tumor / therapy
  • [MeSH-minor] Child. Combined Modality Therapy. Drug Resistance, Neoplasm. Humans. Neoplasm Recurrence, Local. Prognosis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954292.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 60
  •  go-up   go-down


10. Corapcioglu F, Dillioğlugil O, Sarper N, Akansel G, Calişkan M, Arisoy AE: Spinal cord compression and lung metastasis of Wilms' tumor in a pregnant adolescent. Urology; 2004 Oct;64(4):807-10
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal cord compression and lung metastasis of Wilms' tumor in a pregnant adolescent.
  • Wilms' tumor in adults is rare, and no treatment guidelines have been established.
  • In this case report, we present a 19-year-old adolescent with recurrent Wilms' tumor, a paraspinal dumbbell mass, metastatic involvement of the vertebral bodies, lung metastasis, and pregnancy.
  • To our knowledge, this is the first report of a pregnant patient with Wilms' tumor who had to undergo immediate chemotherapy with vincristine and actinomycin-D owing to spinal cord compression at 25 weeks of pregnancy.
  • No teratogenic or other toxic effects of vincristine or actinomycin-D were observed in the fetus.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / complications. Kidney Neoplasms / drug therapy. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / drug therapy. Polyradiculopathy / etiology. Pregnancy Complications, Neoplastic / drug therapy. Spinal Cord Compression / etiology. Wilms Tumor / complications. Wilms Tumor / drug therapy
  • [MeSH-minor] Abdominal Pain / etiology. Adolescent. Bone Neoplasms / drug therapy. Bone Neoplasms / radiotherapy. Bone Neoplasms / secondary. Carboplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Dactinomycin / adverse effects. Dexamethasone / administration & dosage. Etoposide / administration & dosage. Female. Fetus / drug effects. Humans. Ifosfamide / administration & dosage. Infant, Newborn. Lumbar Vertebrae. Patient Dropouts. Pregnancy. Remission Induction. Vincristine / administration & dosage. Vincristine / adverse effects


11. Gandhi S, Meech SJ, Puthawala MA, Ferguson WS, Cardarelli GA, Dupuy DE: Combined computed tomography-guided radiofrequency ablation and brachytherapy in a child with multiple recurrences of Wilms' tumor. J Pediatr Hematol Oncol; 2005 Jul;27(7):377-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined computed tomography-guided radiofrequency ablation and brachytherapy in a child with multiple recurrences of Wilms' tumor.
  • BACKGROUND: Treatment of relapsed Wilms' tumor remains a challenge.
  • We describe a case of an 11-year-old girl with multiply relapsed Wilms' tumor in whom combined percutaneous computed tomography (CT)-guided radiofrequency ablation and brachytherapy directed at a retroperitoneal tumor mass resulted in pain palliation and local tumor control.
  • OBSERVATIONS: Over the course of few weeks, her requirement for narcotic pain medications dramatically decreased.
  • A contrast-enhanced CT scan obtained at 8 months after the procedure showed no evidence for local tumor recurrence.
  • However, she subsequently developed myelodysplasia with evolution into leukemia, presumably secondary to chemotherapy, and died 9.5 months after the procedure.
  • CONCLUSION: Combined CT-guided radiofrequency ablation and brachytherapy is a promising new minimally invasive palliative treatment of recurrent Wilms' tumor.
  • [MeSH-major] Kidney Neoplasms / radiotherapy. Wilms Tumor / radiotherapy
  • [MeSH-minor] Biopsy. Brachytherapy. Child. Female. Humans. Neoplasm Recurrence, Local. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16012327.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Metzger ML, Stewart CF, Freeman BB 3rd, Billups CA, Hoffer FA, Wu J, Coppes MJ, Grant R, Chintagumpala M, Mullen EA, Alvarado C, Daw NC, Dome JS: Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study. J Clin Oncol; 2007 Jul 20;25(21):3130-6
Hazardous Substances Data Bank. Topotecan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study.
  • PURPOSE: A phase II study was conducted to evaluate the activity and safety of topotecan in pediatric patients with recurrent Wilms' tumor.
  • PATIENTS AND METHODS: Patients with favorable histology Wilms' tumor (FHWT) and recurrence after at least one salvage chemotherapy regimen or with anaplastic histology Wilms' tumor (AHWT) in first or subsequent recurrence were eligible.
  • Treatment dosages were adjusted to achieve a target area under the curve (AUC) of 80 +/- 10 ng/mL*h.
  • Tumor responses were measured after two cycles of treatment.
  • CONCLUSION: Topotecan administered on a protracted schedule is active against recurrent FHWT.
  • Inclusion of topotecan in front-line clinical trials for patients with recurrent Wilms' tumor should be considered.
  • [MeSH-major] Kidney Neoplasms / drug therapy. Neoplasm Recurrence, Local / diagnosis. Topotecan / therapeutic use. Wilms Tumor / drug therapy. Wilms Tumor / mortality
  • [MeSH-minor] Area Under Curve. Child. Child, Preschool. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Immunohistochemistry. Infusions, Intravenous. Male. Maximum Tolerated Dose. Neoplasm Staging. Prognosis. Risk Assessment. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17634492.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / CA-23099
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7M7YKX2N15 / Topotecan
  •  go-up   go-down


13. Pascual Samaniego M, Calleja Escudero J, Alvarez Gago T, Gonzalo Rodríguez V, Müller Arteaga C, Fernández del Busto E: [Adult Wilms' tumor]. Actas Urol Esp; 2004 Jul-Aug;28(7):544-8
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adult Wilms' tumor].
  • [Transliterated title] Tumor de Wilms del adulto.
  • Wilms' tumor is a malignant embryonic renal neoplasm that is exceptional in adults.
  • There are not clinical data or radiographic investigations that can distinguish it from renal cell carcinoma.
  • It may be cystic and must be consider in the differential diagnosis of cystic lesions of the kidney.
  • The prognosis of Wilms' tumor in adults is worse than in children because of the high recurrence, the lower response rate to chemotherapy regimens and the advanced stage at the time of clinical presentation, like an asymptomatic abdominal mass in 75% of the cases.
  • We report a new case of nephroblastoma in a 29 years old woman presenting like a renal colic, with a cystic configuration by abdominal ultrasound initially, that changed into a solid renal mass later.
  • There is not a definitive treatment protocol currently but some authors suggest a combination chemotherapy with carboplatin and etoposide because it is very effective in recurrent or refractory adult Wilms' tumor.
  • [MeSH-major] Kidney / pathology. Kidney Neoplasms / pathology. Wilms Tumor / pathology
  • [MeSH-minor] Adult. Female. Humans. Nephrectomy / methods. Tomography, X-Ray Computed. Treatment Outcome. Urography

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15384282.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


14. Olaya Vargas A, Castellanos Toledo A, Rivera Luna R, Cardenas Cardos R, Rivera Ramirez A, Gonzalez Perez R, Escamilla Asiain G: Gemcitabine based chemotherapy in recurrent or advanced pediatric solid tumors: A phase II study. J Clin Oncol; 2004 Jul 15;22(14_suppl):8574

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine based chemotherapy in recurrent or advanced pediatric solid tumors: A phase II study.
  • Advances have been made in treating these patients over the last three decades by apropiate therapy.
  • This dramatic improvement in outcome has led to the estimation that in the year 2000, one in every 1,000 young adults between the ages 20 and 29 years would have been a survivor of childhood cancer; and this due to the chemotherapy.
  • Patients had recurrent or refractory solid tumor; TREATMENT: Gemcitabine alone 800 mg/m2 days 1 and 8 or in combination with cisplatin at 80 mg/m2 day 1.
  • RESULTS: The median age was 7.7 years (2-17) The histopathology was 2 pts with Ewing sarcoma, 2 pts germ cell tumors, 1 pt Wilms tumor, 2 pt rhabdomiosarcoma, 1 pt rethnoblastoma, 1 pt ostheosacoma and 1 pt hepatoblastoma.
  • All patients were previous treated with chemotherapy: 5 pts received VAC (vincristine, adryamicin and cyclophospamide); 3 received ICE (Ifosfamide, cyclophospamide and epirubicin); and 3 pts received: VeIP, VAI and ethoposide- carboplatin.
  • There were 24 courses of chemotherapy.
  • Conclusión: Gemcitabine alone or in combination with cisplatin demostrated some efficacy in patients heavly previous treated with good tolerance, it could be an option for rescue treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013923.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Kist-van Holthe JE, Ho PL, Stablein D, Harmon WE, Baum MA: Outcome of renal transplantation for Wilms' tumor and Denys-Drash syndrome: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant; 2005 Jun;9(3):305-10
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of renal transplantation for Wilms' tumor and Denys-Drash syndrome: a report of the North American Pediatric Renal Transplant Cooperative Study.
  • In some children with bilateral Wilms' tumor, reduction of tumor burden cannot be accomplished without total nephrectomy.
  • In Denys-Drash syndrome, nephrectomy is required for associated Wilms' tumor or after progression to end stage renal disease secondary to diffuse mesangial sclerosis because of risk of development of Wilms' tumor.
  • Current recommendation is to wait at least 1-2 yr after completion of chemotherapy for Wilms' tumor before renal transplantation.
  • The North American Pediatric Renal Transplant Cooperative Study dialysis (1992-2001) and transplant registries (1987-2002) were analyzed, comparing children 0-18 yr old with Wilms' tumor and Denys-Drash syndrome to other primary diagnoses.
  • There were 37 children with Wilms' tumor and 33 with Denys-Drash syndrome in the dialysis registry.
  • Of these, 10 children with Wilms' tumor and three with Denys-Drash syndrome did not receive a renal transplant and all died.
  • The cause of death was Wilms' tumor in eight children with Wilms' tumor and in one with Denys-Drash syndrome.
  • The transplant registry included 43 children with Wilms' tumor, 43 children with Denys-Drash syndrome, and 7469 patients with other diagnoses.
  • There were no graft failures or deaths because of recurrent Wilms' tumor in the Drash group.
  • There was one death with Wilms' tumor in the Wilms' group - a 2.5-yr-old child transplanted after 6 months of dialysis who died of Wilms' <6 months after renal transplantation.
  • In conclusion, most children dialyzed because of Wilms' tumor and Denys-Drash syndrome who did not receive a renal transplant died of Wilms' tumor.
  • However, the outcomes of children with Wilms' tumor and Denys-Drash syndrome who proceeded to renal transplantation are comparable with children with other diagnoses, with no graft failures because of recurrence and only one death from Wilms' tumor in a Wilms' patient who received only a short course of dialysis prior to transplantation.
  • Current practices in children with Wilms' tumor and Denys-Drash syndrome appear to be on target to portend good outcome following renal transplantation.
  • [MeSH-major] Denys-Drash Syndrome / surgery. Kidney Neoplasms / surgery. Treatment Outcome. Wilms Tumor / surgery
  • [MeSH-minor] Adolescent. Child. Female. Graft Survival. Humans. Infant. Kidney Transplantation. Male. Renal Dialysis


16. Shearer P, Kapoor G, Beckwith JB, Takashima J, Breslow N, Green DM: Secondary acute myelogenous leukemia in patients previously treated for childhood renal tumors: a report from the National Wilms Tumor Study Group. J Pediatr Hematol Oncol; 2001 Feb;23(2):109-11
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary acute myelogenous leukemia in patients previously treated for childhood renal tumors: a report from the National Wilms Tumor Study Group.
  • PURPOSE: This review characterized cases of secondary acute myelogenous leukemia (AML) occurring after treatment of renal neoplasms on protocols of the National Wilms Tumor Study Group (NWTSG) between October 1969 and December 1991.
  • Referring institutions were contacted by a confidential letter requesting pathology reports, results of immunophenotyping, cytogenetic, and molecular analyses, and details concerning treatment of AML.
  • At the time of diagnosis of Wilms tumor, the median age of the seven patients (4 boys) was 3.2 years.
  • Five of the seven renal neoplasms had favorable histologic characteristics.
  • One patient had bilateral tumors, and two were treated for recurrent Wilms tumor.
  • All patients received chemotherapy regimens that included doxorubicin (6) or etoposide (1), and six were treated with infradiaphragmatic irradiation.
  • The median latency period from initial diagnosis of the renal neoplasm to development of secondary AML was 3 years (range, 1.2-4 yrs).
  • CONCLUSIONS: The development of secondary AML in this subset of patients after treatment of renal neoplasms may reflect the interaction of the effects of treatment and possible genetic predisposition toward cancer.
  • [MeSH-major] Leukemia, Myeloid / epidemiology. Neoplasms, Second Primary / epidemiology. Wilms Tumor / therapy
  • [MeSH-minor] Abnormalities, Multiple / epidemiology. Acute Disease. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Cohort Studies. Comorbidity. Databases, Factual. Female. Fetal Growth Retardation / epidemiology. Humans. Infant. Leukemia, Radiation-Induced / epidemiology. Leukemia, Radiation-Induced / etiology. Male. Neoplasms, Multiple Primary / epidemiology. Radiotherapy, Adjuvant / adverse effects. Retrospective Studies. Survival Analysis. Treatment Outcome. United States / epidemiology

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11216701.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Baker JM, Viero S, Kim PC, Grant RM: Stage III cystic partially differentiated nephroblastoma recurring after nephrectomy and chemotherapy. Pediatr Blood Cancer; 2008 Jan;50(1):129-31
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage III cystic partially differentiated nephroblastoma recurring after nephrectomy and chemotherapy.
  • Cystic partially differentiated nephroblastoma (CPDN) has low malignant potential.
  • We report a 1-year-old with stage III CPDN of the right kidney that recurred following radical nephrectomy and chemotherapy.
  • There was evidence of tumor spillage pre-operatively and intra-operatively.
  • During chemotherapy the disease recurred in the omentum and the peritoneum.
  • Pathology of the recurrent resected cysts revealed a more differentiated biphasic tumor without blastemal elements.
  • Chemotherapy failed to prevent recurrence but only mature elements were present following this treatment.
  • The intensity of therapy required to treat CPDN remains undefined.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / therapy. Nephrectomy. Wilms Tumor / secondary. Wilms Tumor / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Infant. Peritoneal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 16786584.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Garg R, Agarwala S, Bhatnagar V: Acute pancreatitis induced by ifosfamide therapy. J Pediatr Surg; 2010 Oct;45(10):2071-3
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute pancreatitis induced by ifosfamide therapy.
  • Ifosfamide used in the treatment of pediatric solid tumors is known to have serious adverse effects, including acute pancreatitis, a rare complication of therapy.
  • This report describes a young girl who developed acute pancreatitis while being treated for recurrent Wilms tumor with the ifosfamide, carboplatin, and etoposide regimen.
  • She recovered completely and without sequelae from ifosfamide-induced pancreatitis soon after the drug was stopped.
  • Abdominal pain in patients on anticancer treatment is a common occurrence, but it is rarely investigated.
  • Patients who receive ifosfamide as part of a chemotherapy regimen should be carefully monitored, and symptoms or signs suggestive of acute pancreatitis should be promptly investigated.
  • Withholding the drug usually leads to complete recovery.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Ifosfamide / adverse effects. Pancreatitis / chemically induced. Wilms Tumor / drug therapy
  • [MeSH-minor] Acute Disease. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / adverse effects. Carboplatin / therapeutic use. Child. Combined Modality Therapy. Drug-Related Side Effects and Adverse Reactions. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Humans. Recurrence

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20920734.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


19. Manzitti C, Mereu P, Haupt R, Di Blasi A, Bellani FF, Dallorso S: Parotid carcinoma after autologous bone marrow transplantation for relapsed nephroblastoma. J Pediatr Hematol Oncol; 2003 Aug;25(8):672-3
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parotid carcinoma after autologous bone marrow transplantation for relapsed nephroblastoma.
  • Abdominal irradiation, especially if associated with doxorubicin administration, increases the risk of a secondary malignant neoplasm (SMN) after treatment of nephroblastoma.
  • Secondary malignant salivary tumors are rare and usually occur in patients with previous cranial irradiation.
  • The authors describe the case of a parotid mucoepidermoid carcinoma arising 13 years after diagnosis of nephroblastoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / etiology. Carcinoma / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / radiotherapy. Neoplasms, Second Primary / etiology. Parotid Neoplasms / etiology. Parotid Neoplasms / pathology. Wilms Tumor / drug therapy. Wilms Tumor / radiotherapy
  • [MeSH-minor] Adult. Doxorubicin / administration & dosage. Humans. Male. Time Factors

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12902928.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin
  •  go-up   go-down


20. Spreafico F, Bisogno G, Collini P, Jenkner A, Gandola L, D'Angelo P, Casazza G, Piva L, Luksch R, Perotti D, Pession A, Fagioli F, Dallorso S: Treatment of high-risk relapsed Wilms tumor with dose-intensive chemotherapy, marrow-ablative chemotherapy, and autologous hematopoietic stem cell support: experience by the Italian Association of Pediatric Hematology and Oncology. Pediatr Blood Cancer; 2008 Jul;51(1):23-8
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of high-risk relapsed Wilms tumor with dose-intensive chemotherapy, marrow-ablative chemotherapy, and autologous hematopoietic stem cell support: experience by the Italian Association of Pediatric Hematology and Oncology.
  • BACKGROUND: We evaluated an intensified chemotherapy strategy in children with Wilms tumor who relapsed with high-risk features.
  • PROCEDURES: From January 2001 to June 2006, we treated 20 consecutive children with reinduction chemotherapy (using ifosfamide/carboplatin/etoposide in 15/20 cases), with (n = 15) or without (n = 5) subsequent high-dose chemotherapy and hematopoietic stem cell support, surgery where feasible, and radiation therapy.
  • The median time to relapse was 10 months after nephrectomy.
  • All but two children initially received doxorubicin as first-line therapy.
  • RESULTS: All patients were assessed for outcome: 13 are currently alive, 12 of them in remission a median 25 months since their relapse, one with progressing tumor.
  • The treatment was unsuccessful in eight children: the disease progressed during reinduction in three, and relapsed in five.
  • CONCLUSION: A disease-free survival rate nearing 50% is a realistic target in children with high-risk recurrent Wilms tumor.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Salvage Therapy / methods. Transplantation Conditioning / methods. Wilms Tumor / therapy
  • [MeSH-minor] Child. Child, Preschool. Female. Graft Survival. Humans. Infant. Italy. Male. Nephrectomy. Remission Induction. Survival Rate. Transplantation, Autologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18293386.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


21. Spreafico F, Bellani FF: Wilms' tumor: past, present and (possibly) future. Expert Rev Anticancer Ther; 2006 Feb;6(2):249-58
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wilms' tumor: past, present and (possibly) future.
  • Wilms' tumor is one of the successes of pediatric oncology, with an overall cure rate of over 85%, using relatively simple therapies.
  • The results that have been achieved in children with Wilms' tumors support the strong value of the multidisciplinary team approach to cancer.
  • The two largest cooperative groups that have studied the optimum treatment for Wilms' tumor are the National Wilms' Tumor Study group in North America and the International Society of Pediatric Oncology, involving European and other countries.
  • The National Wilms' Tumor Study group recommends primary surgery before any adjuvant treatment, whereas the International Society of Pediatric Oncology trials are based on the use of preoperative chemotherapy.
  • The debate on primary chemotherapy versus primary nephrectomy appears to have been overcome, in the sense that the advantages and disadvantages of these two diverse methods have emerged from large and well-performed clinical trials, and comparably low doses of anthracyclines and radiotherapy are now used.
  • Challenges remain in identifying novel molecular, histological and clinical risk factors for stratification of treatment intensity.
  • This could allow a safe reduction in therapy for patients known to have an excellent chance of cure with the current therapy, while identifying, at diagnosis, the minority of children at risk of relapse, who will necessitate more aggressive treatments.
  • Another positive factor is the substantial progress that has been made in the cure for recurrent patients, with long-term survivals shifting from 30 to almost 60% in more recently treated patients with intensive-dose chemotherapy regimens.
  • The combination of lower relapses and higher salvage rates translated into significantly improved overall survival for Wilms' tumor patients as a whole.
  • This review covers current concepts on treatment strategies for Wilms' tumor, with an overview of the results and achievements of the important clinical trials.
  • [MeSH-major] Kidney Neoplasms / drug therapy. Kidney Neoplasms / surgery. Wilms Tumor / drug therapy. Wilms Tumor / surgery
  • [MeSH-minor] Age Factors. Chemotherapy, Adjuvant. Child. Child, Preschool. Clinical Trials as Topic. Combined Modality Therapy. Humans. Neoadjuvant Therapy. Neoplasm Staging. Risk Assessment. Salvage Therapy. Survival Analysis

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445377.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 80
  •  go-up   go-down


22. MacRae R, Grimard L, Hsu E, Nizalik E, Halton JM: Brain metastases in Wilms' tumor: case report and literature review. J Pediatr Hematol Oncol; 2002 Feb;24(2):149-53
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastases in Wilms' tumor: case report and literature review.
  • A 2-year-old girl who had a stage 2, favorable-histology Wilms tumor diagnosed when she was age 10 months presented with multiple brain metastases at second recurrence.
  • She had been treated with combined radiotherapy, surgery, and chemotherapy; at 2 months after treatment, recurrent disease developed in the central nervous system and she died.
  • Brain metastases are rare in the natural history of Wilms tumor.
  • Although it does not appear that cerebral metastases are a barrier to tumor eradication and long-term survival if treated with combined modality therapy, treatment should be individualized.
  • [MeSH-major] Brain Neoplasms / secondary. Frontal Lobe. Kidney Neoplasms. Occipital Lobe. Parietal Lobe. Wilms Tumor / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Combined Modality Therapy. Craniotomy. Fatal Outcome. Female. Humans. Ifosfamide / administration & dosage. Infant. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / secondary. Mediastinal Neoplasms / surgery. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Nephrectomy. Palliative Care. Paresis / etiology. Thoracotomy

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11990704.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 25
  •  go-up   go-down


23. McAlpine J, Azodi M, O'Malley D, Kelly M, Golenewsky G, Martel M, Rutherford T, Tavassoli F: Extrarenal Wilms' tumor of the uterine corpus. Gynecol Oncol; 2005 Mar;96(3):892-6
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extrarenal Wilms' tumor of the uterine corpus.
  • BACKGROUND: Extrarenal Wilms' tumors (EWT) are rare.
  • A case of uterine Wilms' tumor in an adult is presented with a review of the literature.
  • She was surgically staged, received chemotherapy, and is without evidence of disease at 1 year follow-up.
  • CONCLUSIONS: Prognosis and treatment of EWT may differ by location and patient age.
  • Literature review of uterine Wilms' tumor reveals favorable outcome with (1) focal disease confined to the uterus and (2) adequate surgery, including hysterectomy.
  • The National Wilms' Tumor Study Group recommends adjuvant chemotherapy for all EWT.
  • Radiation may be reserved for patients with residual, metastatic and/or recurrent disease.
  • [MeSH-major] Uterine Neoplasms / pathology. Wilms Tumor / pathology

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721447.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


24. Benesch M, Windelberg M, Sauseng W, Witt V, Fleischhack G, Lackner H, Gadner H, Bode U, Urban C: Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann Oncol; 2008 Apr;19(4):807-13
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors.
  • PATIENTS AND METHODS: Fifteen patients (male: n = 8; female: n = 7; median age, 14.6 years) received bevacizumab for recurrent or progressive solid tumors (carcinoma: n = 3; neuroblastoma: n = 2; astrocytoma grade III: n = 2; rhabdomyosarcoma: n = 2; nephroblastoma: n = 2; benign vascular tumors: n = 2; synovial sarcoma: n = 1; and malignant hemangiopericytoma: n = 1) on a compassionate basis.
  • Most patients received chemotherapy in addition to bevacizumab.
  • Duration of bevacizumab therapy ranged from 1.5 to 23 months.
  • CONCLUSIONS: Bevacizumab seems to have a good acute safety profile and some antitumor activity in heavily pretreated children and young adults with recurrent solid tumors.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056650.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


25. Czauderna P, Katski K, Kowalczyk J, Kurylak A, Lopatka B, Skotnicka-Klonowicz G, Sawicz-Birkowska K, Godziński J: Venoocclusive liver disease (VOD) as a complication of Wilms' tumour management in the series of consecutive 206 patients. Eur J Pediatr Surg; 2000 Oct;10(5):300-3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Venoocclusive liver disease (VOD) as a complication of Wilms' tumour management in the series of consecutive 206 patients.
  • In 4 years (1993-1996) 206 pts. with nephroblastoma were treated.
  • It results from damage to the endothelium of hepatic venules and necrosis of central hepatocytes with subsequent proliferation of fibrous tissue and occlusion of the central hepatic veins.
  • Dactinomycin is one of the drugs considered responsible for its development.
  • In all cases, VOD occurred during postoperative chemotherapy (mean 16 th week of treatment).
  • Five children with right kidney tumors underwent post-operative abdominal irradiation.
  • However, in 2 cases recurrent VOD episodes were noted.
  • All children received supportive treatment only.
  • In 6 cases, VOD resulted in chemotherapy delay or drug reductions, while in 4 others chemotherapy was completed preliminarily.
  • CONCLUSIONS: Total 5% VOD frequency is similar to other reports.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Drug-Induced Liver Injury / etiology. Hepatic Veno-Occlusive Disease / chemically induced. Kidney Neoplasms / drug therapy. Lomustine / adverse effects. Vincristine / adverse effects. Wilms Tumor / drug therapy
  • [MeSH-minor] Adolescent. Cause of Death. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Male. Survival Rate

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11194540.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; SIOP-I protocol
  •  go-up   go-down


26. Adamson PC, Matthay KK, O'Brien M, Reaman GH, Sato JK, Balis FM: A phase 2 trial of all-trans-retinoic acid in combination with interferon-alpha2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch, NCI and Children's Oncology Group Study. Pediatr Blood Cancer; 2007 Oct 15;49(5):661-5
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 2 trial of all-trans-retinoic acid in combination with interferon-alpha2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch, NCI and Children's Oncology Group Study.
  • BACKGROUND: The combination of the antiproliferative and differentiation-inducing effects of retinoids together with the antiproliferative, immunostimulatory, and differentiation-potentiating effects of interferon-alpha (IFN-alpha) were the basis for the development of this combination in pediatric patients with refractory neuroblastoma or Wilms tumor.
  • PROCEDURE: A phase 2 trial of all-trans-retinoic acid (ATRA), administered orally at a dose of 90 mg/m(2)/day in three divided doses for 3 consecutive days per week, and IFN-alpha2a, administered subcutaneously daily at a dose of 3 x 10(6) U/m(2)/day for 5 consecutive days per week, in 4 week cycles was performed.
  • RESULTS: Seventeen patients (16 evaluable) with neuroblastoma, median age 9 years, and 15 patients (14 evaluable) with Wilms tumor, median age 6 years, were enrolled.
  • CONCLUSIONS: The combination of ATRA and IFN-alpha2a was inactive in children with relapsed or refractory neuroblastoma and Wilms tumor.
  • The lack of activity with this combination in children with refractory neuroblastoma is similar to the disappointing phase 2 results of single agent 13-cis-retinoic-acid (13cRA) and does not support further development of ATRA for children with relapsed neuroblastoma.
  • [MeSH-major] Interferon-alpha / administration & dosage. Neuroblastoma / drug therapy. Tretinoin / administration & dosage. Wilms Tumor / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Drug Therapy, Combination. Humans. Infant. Recombinant Proteins. Remission Induction. Salvage Therapy / methods. Treatment Outcome


27. Jurkiewicz E, Pakuła-Kościesza I, Drogosiewicz M, Dembowska-Bagińska B, Perek D: [The value of the proton magnetic resonance spectroscopy (HMRS) of white matter injury in children treated with chemo- and/or radiotherapy. Preliminary report]. Med Wieku Rozwoj; 2003 Apr-Jun;7(2):249-60
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • THE AIM of this study was to estimate the value of HMRS in the diagnosis of brain lesions observed in children treated with chemo and radiotherapy and to assess the possibility to differentiate these lesions from neoplasm or recurrent disease.
  • MATERIALS AND METHOD: We examined 6 children, aged from 7 to 15 yrs, 3 with brain tumours, 1 with esthesioneuroblastoma treated with chemo and radiotherapy and 2 patients with chemotherapy only, for other neoplasms (leukemia, Wilms tumor).
  • RESULTS: In all cases MRI showed extensive hyperintensive changes in brain tissue with significant mass effect.
  • In 3 cases HMRS was within normal limits, in other 3 cases moderately elevated peak of choline and peak of lactate and lipids were found.
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant / adverse effects. Child. Combined Modality Therapy. Diagnosis, Differential. Esthesioneuroblastoma, Olfactory / drug therapy. Esthesioneuroblastoma, Olfactory / radiotherapy. Female. Follow-Up Studies. Humans. Leukemia / drug therapy. Leukemia / radiotherapy. Male. Neoplasm Recurrence, Local / diagnosis. Nose Neoplasms / drug therapy. Nose Neoplasms / radiotherapy. Poland. Protons. Radiotherapy, Adjuvant / adverse effects. Sensitivity and Specificity. Time Factors. Wilms Tumor / drug therapy. Wilms Tumor / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12878796.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


28. Kulkarni R, Wolf JS Jr, Padiyar N, Zuckerman L, Gera R, Scott-Emuakpor AB: Severe intrarenal fibrosis, infundibular stenosis, renal cysts, and persistent perilobar nephrogenic rests in a patient with Beckwith-Wiedemann syndrome 27 years after diffuse nephroblastomatosis and Wilms tumor: natural progression or a consequence of treatment? J Pediatr Hematol Oncol; 2002 Jun-Jul;24(5):389-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe intrarenal fibrosis, infundibular stenosis, renal cysts, and persistent perilobar nephrogenic rests in a patient with Beckwith-Wiedemann syndrome 27 years after diffuse nephroblastomatosis and Wilms tumor: natural progression or a consequence of treatment?
  • She was diagnosed in infancy with Beckwith-Wiedemann syndrome and bilateral multifocal perilobar nephrogenic rests that progressed to diffuse nephroblastomatosis with neoplastic nephroblastomatous rests at 14 months of age and subsequently to a right Wilms tumor at 5 years of age.
  • Computed tomography of the abdomen during the current admission showed multiple obstructed calices.
  • Ureteroscopic inspection of the left kidney revealed severe intrarenal scarring with multiple infundibular stenosis, hydrocalices, and nephrocalcinosis.
  • Renal biopsy showed sclerotic glomeruli with calcification and scarring and persistent subcapsular nodular renal blastema.
  • After discharge, the patient has had two or three episodes of recurrent pain associated with new areas of infundibular stenoses and renal cysts.
  • Bilateral nephrectomy and renal transplantation is being considered for management of progressive disease and relief of intractable pain.
  • The potential causes of progressive and severe intrarenal fibrosis, infundibular stenosis and nephrocalcinosis, and renal cysts in this patient may include abnormal renal development secondary to Beckwith-Wiedemann syndrome itself, radiation or chemotherapy damage, or a combination.
  • [MeSH-major] Beckwith-Wiedemann Syndrome / complications. Kidney / pathology. Kidney Calculi / etiology. Kidney Diseases, Cystic / etiology. Kidney Neoplasms / complications. Wilms Tumor / complications
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Disease Progression. Female. Fibrosis. Humans. Kidney Transplantation. Nephrectomy. Radiotherapy. Tomography, X-Ray Computed


29. Szavay P, Luithle T, Semler O, Graf N, Fuchs J: Surgery of cavoatrial tumor thrombus in nephroblastoma: a report of the SIOP/GPOH study. Pediatr Blood Cancer; 2004 Jul;43(1):40-5
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery of cavoatrial tumor thrombus in nephroblastoma: a report of the SIOP/GPOH study.
  • BACKGROUND: Resection of a Wilms tumor extending through the inferior vena cava into the right atrium represents a challenge to the pediatric surgeon.
  • Exact preoperative diagnosis is essential to identify the tumor and its intravascular extension.
  • To achieve a complete excision of the tumor cardiopulmonary bypass and hypothermia may be required.
  • The feasibility of a complete resection is important as it guides subsequent therapy such as chemotherapy and radiation.
  • PROCEDURE: In order to define these issues, we reviewed the records of 33 of 1,151.
  • Patients enrolled in the SIOP 93-01/GPOH Study and the SIOP 2001/GPOH Study who had a tumor thrombus into the inferior vena cava and into the right atrium.
  • Twenty-four patients had a tumor thrombus into the inferior vena cava, in nine patients the thrombus reached into the right atrium.
  • Twenty-nine children are still alive; four patients died, one patient due to aspiration and failed resuscitation, two patients died from a recurrent tumor, and one child due to an unresectable primary tumor.
  • CONCLUSION: Our report suggests that Wilms tumor extending to the inferior vena cava and the right atrium is technical challenging, but with adequate preoperative diagnosis and a multidisciplinary surgical approach including cardiopulmonary bypass and hypothermia, the prognosis is favorable.
  • [MeSH-major] Cardiopulmonary Bypass. Heart Atria. Kidney Neoplasms / surgery. Thrombosis / surgery. Vena Cava, Inferior. Wilms Tumor / surgery
  • [MeSH-minor] Child. Child, Preschool. Combined Modality Therapy. Female. Germany / epidemiology. Humans. Hypothermia, Induced. Infant. Intraoperative Complications / epidemiology. Male. Neoplasm Invasiveness. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15170888.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Murphy JJ, Tawfeeq M, Chang B, Nadel H: Early experience with PET/CT scan in the evaluation of pediatric abdominal neoplasms. J Pediatr Surg; 2008 Dec;43(12):2186-92
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Positron emission tomography/computerized tomography (PET/CT) scan provides both functional and anatomical information in a single diagnostic test.
  • It has the potential to be a valuable tool in the evaluation of pediatric abdominal tumors.
  • These included Burkitt's lymphoma (8), neuroblastoma (7), rhabdomyosarcoma (6), ovarian tumor (3), Wilms' tumor (2), hepatocellular carcinoma (2), paraganglioma (1), germ cell tumor (1), undifferentiated sarcoma (1), renal primitive neuroectodermal tumor (1), gastrointestinal stromal tumor (1), adrenocortical carcinoma (1), inflammatory pseudotumor (1), and adrenal adenoma (1).
  • These include (1) preoperative staging, (2) selection of appropriate site for biopsy, (3) identification of occult metastatic disease, (4) follow-up for residual or recurrent disease, and (5) assessment of response to chemotherapy.
  • [MeSH-major] Abdominal Neoplasms / radiography. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Drug Monitoring. Female. Fluorodeoxyglucose F18 / pharmacokinetics. Humans. Male. Neoplasm Staging / methods. Neoplasm, Residual. Postoperative Care / methods. Preoperative Care / methods. Radiopharmaceuticals / pharmacokinetics. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19040932.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


31. Oue T, Kubota A, Okuyama H, Kawahara H, Inoue M, Yagi K, Kawa K: Megatherapy with hematopoietic stem cell rescue as a preoperative treatment in unresectable pediatric malignancies. J Pediatr Surg; 2003 Jan;38(1):130-3; discussion 130-3
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Megatherapy with hematopoietic stem cell rescue as a preoperative treatment in unresectable pediatric malignancies.
  • BACKGROUND/PURPOSE: To improve the quality of life and prognosis of the patients with advanced pediatric malignant tumors, the authors have used megatherapy (MT) with hematopoietic stem cell transplantation (SCT) before surgery.
  • To elucidate the impact of preoperative MT on the treatments of pediatric advanced malignancies, the authors reviewed the timing of surgery, preoperative condition, postoperative recovery, and outcome.
  • METHODS: Between 1991 and 2001, 24 children with malignant tumors received MT with SCT before surgery, and 19 tumors were resected after SCT.
  • These tumors included 12 neuroblastomas, 2 hepatic tumors, 2 peripheral primitive neuroectodermal tumors, one rhabdomyosarcoma, one Wilms' tumor, and one yolk sac tumor.
  • The tumors were resected completely in 14 cases (73.7%), and complete remission (CR) was achieved after surgery in 9 cases (47.4%).
  • At 7 months to 7 years after diagnosis, 9 patients are alive without disease, one with disease, 6 have died of recurrent tumor, and 2 have died of chemotherapy-associated complications.
  • In the treatment of advanced pediatric malignancies, especially in the case of unresectable tumor, preoperative MT with SCT should be considered.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Neoplasms / drug therapy. Neoplasms / therapy. Preoperative Care / methods
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Drug Administration Schedule. Female. Humans. Infant. Male

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003, Elsevier Science (USA). All rights reserved.
  • (PMID = 12592635.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Takamizawa S, Scott D, Wen J, Grundy P, Bishop W, Kimura K, Sandler A: The survivin:fas ratio in pediatric renal tumors. J Pediatr Surg; 2001 Jan;36(1):37-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The survivin:fas ratio in pediatric renal tumors.
  • BACKGROUND/PURPOSE: Apoptosis factors inducing or preventing cell death may govern the behavior of certain tumors.
  • Fas is a pro-apoptotic receptor that induces cell death when bound by its ligand and is expressed at greater levels in pediatric renal tumors of good prognosis.
  • Survivin is a novel inhibitor of apoptosis that is expressed in a cell cycle-dependent manner and is abundantly expressed in several tumors of unfavorable histology.
  • This study evaluates the expression of survivin, as well as the prognostic value of the survivin:fas ratio in various types and stages of pediatric renal tumors.
  • METHODS: Multiple apoptosis mRNA species were quantified by Rnase protection assay (RPA) in 32 pediatric renal tumors and adjacent normal kidney specimens before chemotherapy: Wilms' tumor (WT), n = 9; clear cell sarcoma (CCS), n = 4; rhabdoid tumor of the kidney (RTK), n = 5; mesoblastic nephroma (MN), n = 3 and normal kidney, n = 11.
  • RESULTS: Pediatric renal tumors express greater levels of both pro- and antiapoptotic factors than normal kidney.
  • Survivin and fas appeared to be expressed differentially in the tumor specimens sampled.
  • Five of 10 (50%) tumors that went on to recur expressed survivin, whereas survivin was present in only 2 of 11 (18%) nonrecurrent tumors.
  • Conversely, only 2 of 10 (20%) tumors that recurred were fas positive, whereas 5 of 11 (45%) tumors that did not recur expressed fas.
  • The mean survivin:fas ratio was significantly greater in the 10 tumors that went on to recur after treatment (4 RTK, 3 CCS, 3 WT), than in tumors not recurring (2.16+/-1.4 v 1.0+/-1.07; P =.01, Kruskal-Wallis test).
  • The positive predictive value of tumor recurrence was 85.7% (CI: 42.1%, 99.6%) and the negative predictive value was 71.4% (CI: 41.9%, 91.6%) when a cutoff ratio of 1.6 was considered.
  • CONCLUSIONS: The survivin:fas mRNA ratio is of prognostic value in its ability to predict recurrent disease in children undergoing treatment for pediatric renal tumors.
  • In this series, a ratio of greater than 1.6 predicted recurrent disease with a high probability irrespective of clinical stage or pathologic type.
  • Determining the survivin:fas ratio may guide treatment, follow-up and counseling of patients with pediatric renal tumors.
  • [MeSH-major] Antigens, CD95 / metabolism. Kidney Neoplasms / metabolism. Microtubule-Associated Proteins. Proteins / metabolism. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11150435.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proteins; 0 / RNA, Messenger
  •  go-up   go-down


33. Termuhlen AM, Grovas A, Klopfenstein K, Rosselet R, Gross TG: Autologous hematopoietic stem cell transplant with melphalan and thiotepa is safe and feasible in pediatric patients with low normalized glomerular filtration rate. Pediatr Transplant; 2006 Nov;10(7):830-4
Hazardous Substances Data Bank. THIO-TEPA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three patients with nGFR < 60 mL/min/1.73 m(2) enrolled on an institutional phase I trial of HSCT preparative therapy for advanced and recurrent solid tumors with escalating melphalan, ranging from 135 to 180 mg/m(2), thiotepa (600 mg/m(2)), and vincristine (2 mg/m(2)).
  • An additional patient with low nGFR was treated with the same preparative therapy.
  • None of the patients developed acute renal failure, excess toxicities during HSCT or delayed engraftment.
  • These cases demonstrate that it is feasible and safe to perform HSCT in pediatric patients with low nGFR using melphalan- and thiotepa-based preparative therapy.
  • [MeSH-major] Glomerular Filtration Rate / physiology. Hematopoietic Stem Cell Transplantation. Kidney Neoplasms / therapy. Melphalan / therapeutic use. Neuroblastoma / therapy. Thiotepa / therapeutic use. Wilms Tumor / therapy
  • [MeSH-minor] Antineoplastic Agents, Alkylating / therapeutic use. Child, Preschool. Combined Modality Therapy. Drug Therapy, Combination. Female. Humans. Infant. Transplantation, Autologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17032431.001).
  • [ISSN] 1397-3142
  • [Journal-full-title] Pediatric transplantation
  • [ISO-abbreviation] Pediatr Transplant
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial, Phase I; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 905Z5W3GKH / Thiotepa; Q41OR9510P / Melphalan
  •  go-up   go-down


34. Hale GA: Autologous hematopoietic stem cell transplantation for pediatric solid tumors. Expert Rev Anticancer Ther; 2005 Oct;5(5):835-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous hematopoietic stem cell transplantation for pediatric solid tumors.
  • While advances in the treatment of pediatric cancers have increased cure rates, children with metastatic or recurrent solid tumors have a dismal prognosis despite initial transient responses to therapy.
  • While clearly demonstrated to improve outcomes in patients with metastatic neuroblastoma, autologous hematopoietic stem cell transplantation is also frequently used to treat patients with other high-risk diseases such as Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms' tumor, retinoblastoma, germ cell tumors, lymphomas and brain tumors.
  • These published literature demonstrate that autologous hematopoietic stem cell transplantation results in most cases in equivalent or superior outcomes when compared with conventional therapies.
  • Since the inception of autologous hematopoietic stem cell transplantation, regimen-related toxicity has markedly decreased and the vast majority of treatment failures are now due to disease recurrence.
  • Prospective clinical trials are needed to identify specific high-risk patient populations, with randomization (when possible) to compare outcomes of patients undergoing autologous hematopoietic stem cell transplantation with those receiving standard therapy.
  • In addition, investigators need to better define the role of autologous hematopoietic stem cell transplantation in these solid tumors, particularly in combination with other therapeutic modalities such as immunotherapy and novel cell processing methodologies.
  • [MeSH-minor] Child. Combined Modality Therapy. Dose-Response Relationship, Drug. Humans. Neoplasms / therapy. Patient Selection. Randomized Controlled Trials as Topic. Risk Factors. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16221053.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA 21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] England
  • [Number-of-references] 109
  •  go-up   go-down


35. Italiano A, Sirvent N, Michiels JF, Peyrade F, Otto J, Thyss A: Tumour response to paclitaxel in an adult with relapsed nephroblastoma. Lancet Oncol; 2005 Apr;6(4):252-3
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour response to paclitaxel in an adult with relapsed nephroblastoma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Kidney Neoplasms / drug therapy. Paclitaxel / therapeutic use. Pregnancy Complications, Neoplastic / drug therapy. Wilms Tumor / drug therapy
  • [MeSH-minor] Adult. Female. Humans. Neoplasm Recurrence, Local / drug therapy. Pregnancy

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15811622.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down






Advertisement